Skip to main content
SpringerLink
Log in

Prise en charge des cancers du sein métastatique HER2 surexprimé

  • Conference paper
Cancer du sein

  • 268 Accesses

Abstrait

Les cancers du sein métastatiques avec HER2 surexprimé représentent 20 à 30 % des cancers du sein métastatiques. La surexpression de la protéine et l’amplification du gène HER2 sont déterminées selon une méthodologie standardisée (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carlson RW, Moench SJ, Hammond ME et al. (2006) NCCN HER2 Testing in Breast Cancer Task Force. J Natl Compr Canc Netw 4Suppl 3: S1–S22

    Google Scholar 

  2. Zidan J, Dashkovsky I, Stayerman C et al. (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93: 552–556

    Article  PubMed  CAS  Google Scholar 

  3. Gong Y, Booser DJ, Sneige N (2005) Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103: 1763–1769

    Article  PubMed  CAS  Google Scholar 

  4. Gancberg D, Di Leo A, Cardoso F et al. (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036–1043

    Article  PubMed  CAS  Google Scholar 

  5. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  6. Vogel CL, Cobleigh MA, Tripathy D et al. (2002) Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer J Clin Oncol 20: 719–726

    Article  PubMed  CAS  Google Scholar 

  7. Cobleigh MA, Vogel CL, Tripathy D et al. (1999) Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease J Clin Oncol 17: 2639–2648

    PubMed  CAS  Google Scholar 

  8. Konecny GE, Thomssen C, Joachim Lück H et al. (2004) HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer. J Natl Cancer Inst 96: 1141–1151

    PubMed  CAS  Google Scholar 

  9. Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274

    Article  PubMed  CAS  Google Scholar 

  10. Kaufman B, Mackey J, Clemens M et al. (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). Ann Oncol 17(Suppl9): abst LBA2

    Google Scholar 

  11. Gasparini G, Gion M, Mariani L et al. (2006) Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 101: 355–365

    Article  PubMed  CAS  Google Scholar 

  12. Robert N, Leyland-Jones B, Asmar L et al. (2006) Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer J Clin Oncol 24: 2786–2792

    Article  PubMed  CAS  Google Scholar 

  13. Forbes JF, Kennedy J, Pienkowski T et al. (2006) BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive ASCO

    Google Scholar 

  14. Wardley A, Antón-Torres A, Pivot X et al. (2006) metastatic breast cancer (MBC). Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/metastatic breast cancer: primary efficacy results from a randomised phase II study (chat) ESMO2006 Ann Oncol 17(Suppl 9)

    Google Scholar 

  15. Seidman AD, Former MN, Esteva FJ et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587–2595

    PubMed  CAS  Google Scholar 

  16. Esteva FJ, Valero V, Booser D et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–1808

    Article  PubMed  CAS  Google Scholar 

  17. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A et al. (2001) Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 12: 1545–1551

    Article  PubMed  CAS  Google Scholar 

  18. Jahanzeb M, Mortimer JE, Yunus F et al. (2002) Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7: 410–417

    Article  PubMed  CAS  Google Scholar 

  19. Leyland-Jones B, Gelmon K, Ayoub JP et al. (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21: 3965–3971

    Article  PubMed  CAS  Google Scholar 

  20. Burstein HJ, Harris LN, Marcom PK et al. (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21: 2889–2895

    Article  PubMed  CAS  Google Scholar 

  21. Pegram D, Pienkowski T, Northfelt DW et al. (2004) Press, David Reese, Mary-Ann Lindsay, Dennis J. Slamon Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer J Natl Cancer Inst 96: 759–769

    Article  PubMed  CAS  Google Scholar 

  22. Montemurro F, Choa G, Faggiuolo R et al. (2004) A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncol 66: 38–45

    Article  CAS  Google Scholar 

  23. Tedesco KL, Thor AD, Johnson DH et al. (2004) Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3 Overexpressing and Fluorescent in situ Hybridization-Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial. J Clin Oncol 22: 1071–1077

    Article  PubMed  CAS  Google Scholar 

  24. Fountzilas G, Christodoulou C, Tsavdaridis D et al. (2004) Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 22: 655–662

    Article  PubMed  CAS  Google Scholar 

  25. Untch M, Eidtmann H, du Bois A et al. (2004) Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40: 988–997

    Article  PubMed  CAS  Google Scholar 

  26. Perez EA, Suman VJ, Rowland KM et al. (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6: 425–432

    Article  PubMed  CAS  Google Scholar 

  27. Sato N, Sano M, Tabei T et al. (2006) Combination Docetaxel and Trastuzumab Treatment for Patients with HER-2-Overexpressing Metastatic Breast Cancer: A Multicenter, Phase-II Study. Breast Cancer 13: 166–171

    Article  PubMed  Google Scholar 

  28. Chan A, Martin M, Untch M et al. (2006) Vinorelbine plus trastuzumab combination as first-line therapy for HER2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 95: 788–793

    Article  PubMed  CAS  Google Scholar 

  29. Venturini M, Bighin C, Monfardini S et al. (2006) Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 95: 45–53

    Article  PubMed  CAS  Google Scholar 

  30. Chia S, Clemons M, Martin L et al. (2006) Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial. J Clin Oncol 24: 2773–2778

    Article  PubMed  CAS  Google Scholar 

  31. Marcom PK, Isaacs C, Harris L et al. (2006) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102: 43–49

    Article  PubMed  CAS  Google Scholar 

  32. Xu L, Song S, Zhu J et al. (2006) A phase II trial of trastuzumab (H) + capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC), ASCO. J Clin Oncol 24(suppl)

    Google Scholar 

  33. Tusquets I, Ramos M, Gil M et al. (2006) Preliminary results of docetaxel (T) and trastuzumab (H) combination administered every 21 days in metastatic breast cancer (MBC) and HER-2 over-expression patients (P), ASCO. J Clin Oncol 24(Suppl): 10 670

    Google Scholar 

  34. Brufsky A, Fox K, Orlando M et al. (2006) Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression, ASCO. J Clin Oncol 24(suppl)

    Google Scholar 

  35. Baselga J, Carbonell C, Costaneda-Soto NJ et al. (2005) Phase II study of efficacy, safety and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162–2171

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Paoli-Calmettes, 232, bd Sainte-Marguerite, 13273, Marseille cedex 9

    J. -M. Extra

Authors
  1. J. -M. Extra
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this paper

Cite this paper

Extra, J.M. (2007). Prise en charge des cancers du sein métastatique HER2 surexprimé. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-287-71478-8_22

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-71478-8_22

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-71477-1

  • Online ISBN: 978-2-287-71478-8

Publish with us

Policies and ethics

Search

Navigation